A Phase 1 interventional study of Bimekizumab in Healthy Study Participants, sponsored by UCB Biopharma SRL. Terminated at 1 site in Germany. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-10.
Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of the study is to compare the pharmacokinetics (PK) of bimekizumab when administered subcutaneously (sc) as 1x2 mL versus 2x1 mL, using a bimekizumab-safety syringe presentation or bimekizumab-auto-injector presentation, in healthy study participants.
UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Study participant has an active infection or history of infections as follows:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Study participants randomized to this arm will receive bimekizumab administered subcutaneously with bimekizumab-safety syringe-2 mL presentation (test 1).
Drug: Bimekizumab
Study participants randomized to this arm will receive bimekizumab administered subcutaneously with a bimekizumab-safety syringe-1 mL presentation (reference 1).
Drug: Bimekizumab
Study participants randomized to this arm will receive bimekizumab administered subcutaneously with a bimekizumab-auto-injector-2 mL presentation (test 2).
Drug: Bimekizumab
Study participants randomized to this arm will receive bimekizumab administered subcutaneously with a bimekizumab-auto-injector-1 mL (reference 2).
Drug: Bimekizumab
Study participants will receive a single-dose of bimekizumab administered subcutaneously in the Treatment Period.
Also known as: UCB4940, BKZ
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC) for a Single Dose Bimekizumab (BKZ)
AUC is the area under the bimekizumab plasma concentration-time curve from time zero (Day 1 predose) to infinity.
Time frame: From Baseline (Day 1 predose) at predefined time points (up to Day 140)
Area Under the Plasma Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) for a Single Dose Bimekizumab (BKZ)
AUC0-t is the area under the bimekizumab plasma concentration-time curve from time zero (Day 1 predose) to the last observed quantifiable concentration.
Time frame: From Baseline (Day 1 predose) at predefined time points to the last quantifiable concentration (Day 140)
Maximum Plasma Concentration (Cmax) for a Single Dose Bimekizumab (BKZ)
Cmax is the maximum observed plasma concentration.
Time frame: From Baseline (Day 1 predose) at predefined time points (up to Day 140)
Percentage of Participants With at Least One Treatment-emergent Adverse Event (TEAE) From Baseline to End of Safety Follow-Up
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. Treatment-emergent adverse events (TEAEs) were defined as any event not present prior to the administration of IMP or any unresolved event already present before administration of IMP that worsens in intensity following exposure to study treatment.
Time frame: From Baseline (Day 1) to end of Safety Follow-Up (up to Day 140)
Percentage of Participants With at Least One Treatment-emergent Serious Adverse Event (SAE) From Baseline to End of Safety Follow-Up
A serious adverse event (SAE) was defined as any untoward medical occurrence that at any dose: a. Results in death, b. Is life-threatening, c. Requires inpatient hospitalization or prolongation of existing hospitalization, d. Results in persistent disability/incapacity, e. Is a congenital anomaly/ birth defect, f. Other important medical events which based on appropriate medical judgment, jeopardized the study participant and required medical or surgical intervention to prevent any of the above.
Time frame: From Baseline (Day 1) to end of Safety Follow-Up (up to Day 140)
Apparent Terminal Half-life (t1/2)
Apparent terminal half-life, reported in units of days, as determined via simple linear regression (slope=-lambdaz) of natural log (ln) concentration versus time for data points in the terminal phase of the concentration-time curve. t1/2 is calculated as ln2/lambdaz.
Time frame: From Baseline (Day 1 predose) at predefined time points (up to Day 140)
Time of Occurrence of the Maximum Observed Concentration (Tmax) of a Single Dose Bimekizumab (BKZ)
tmax is the time to reach maximum plasma concentration.
Time frame: From Baseline (Day 1 predose) at predefined time points (up to Day 140)
The study started to enroll study participants in February 2020 and concluded in April 2021.
| Milestone | Bimekizumab-SS-2mL (Test 1) | Bimekizumab-SS-2x1mL (Reference 1) | Bimekizumab-AI-2mL (Test 2) | Bimekizumab-AI-2x1mL (Reference 2) |
|---|---|---|---|---|
| Started | 18 | 18 | 17 | 18 |
| Completed | 18 | 18 | 17 | 18 |
| Not completed | 0 | 0 | 0 | 0 |
AUC is the area under the bimekizumab plasma concentration-time curve from time zero (Day 1 predose) to infinity.
| days*micrograms/milliliter (days*ug/mL) | Bimekizumab-SS-2mL (Test 1) | Bimekizumab-SS-2x1mL (Reference 1) | Bimekizumab-AI-2mL (Test 2) | Bimekizumab-AI-2x1mL (Reference 2) |
|---|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC) for a Single Dose Bimekizumab (BKZ) | 1665 ± 34.2 | 1610 ± 31.3 | 1560 ± 19.1 | 1357 ± 35.5 |
AUC0-t is the area under the bimekizumab plasma concentration-time curve from time zero (Day 1 predose) to the last observed quantifiable concentration.
| days*ug/mL | Bimekizumab-SS-2mL (Test 1) | Bimekizumab-SS-2x1mL (Reference 1) | Bimekizumab-AI-2mL (Test 2) | Bimekizumab-AI-2x1mL (Reference 2) |
|---|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) for a Single Dose Bimekizumab (BKZ) | 1551 ± 31.4 | 1509 ± 29.2 | 1469 ± 17.5 | 1296 ± 33.7 |
Cmax is the maximum observed plasma concentration.
| ug/mL | Bimekizumab-SS-2mL (Test 1) | Bimekizumab-SS-2x1mL (Reference 1) | Bimekizumab-AI-2mL (Test 2) | Bimekizumab-AI-2x1mL (Reference 2) |
|---|---|---|---|---|
| Maximum Plasma Concentration (Cmax) for a Single Dose Bimekizumab (BKZ) | 43.56 ± 26.8 | 41.90 ± 23.9 | 42.23 ± 20.3 | 36.94 ± 28.2 |
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. Treatment-emergent adverse events (TEAEs) were defined as any event not present prior to the administration of IMP or any unresolved event already present before administration of IMP that worsens in intensity following exposure to study treatment.
| percentage of participants | Bimekizumab-SS-2mL (Test 1) | Bimekizumab-SS-2x1mL (Reference 1) | Bimekizumab-AI-2mL (Test 2) | Bimekizumab-AI-2x1mL (Reference 2) |
|---|---|---|---|---|
| Percentage of Participants With at Least One Treatment-emergent Adverse Event (TEAE) From Baseline to End of Safety Follow-Up | 66.7 | 44.4 | 70.6 | 38.9 |
A serious adverse event (SAE) was defined as any untoward medical occurrence that at any dose: a. Results in death, b. Is life-threatening, c. Requires inpatient hospitalization or prolongation of existing hospitalization, d. Results in persistent disability/incapacity, e. Is a congenital anomaly/ birth defect, f. Other important medical events which based on appropriate medical judgment, jeopardized the study participant and required medical or surgical intervention to prevent any of the above.
| percentage of participants | Bimekizumab-SS-2mL (Test 1) | Bimekizumab-SS-2x1mL (Reference 1) | Bimekizumab-AI-2mL (Test 2) | Bimekizumab-AI-2x1mL (Reference 2) |
|---|---|---|---|---|
| Percentage of Participants With at Least One Treatment-emergent Serious Adverse Event (SAE) From Baseline to End of Safety Follow-Up | 0 | 0 | 0 | 0 |
Apparent terminal half-life, reported in units of days, as determined via simple linear regression (slope=-lambdaz) of natural log (ln) concentration versus time for data points in the terminal phase of the concentration-time curve. t1/2 is calculated as ln2/lambdaz.
| days | Bimekizumab-SS-2mL (Test 1) | Bimekizumab-SS-2x1mL (Reference 1) | Bimekizumab-AI-2mL (Test 2) | Bimekizumab-AI-2x1mL (Reference 2) |
|---|---|---|---|---|
| Apparent Terminal Half-life (t1/2) | 28.21 ± 17.3 | 27.24 ± 16.8 | 25.73 ± 27.8 | 22.84 ± 28.7 |
tmax is the time to reach maximum plasma concentration.
| days | Bimekizumab-SS-2mL (Test 1) | Bimekizumab-SS-2x1mL (Reference 1) | Bimekizumab-AI-2mL (Test 2) | Bimekizumab-AI-2x1mL (Reference 2) |
|---|---|---|---|---|
| Time of Occurrence of the Maximum Observed Concentration (Tmax) of a Single Dose Bimekizumab (BKZ) | 6.981 (2.99 to 15.0) | 6.988 (2.92 to 12.0) | 6.943 (3.98 to 12.0) | 6.972 (3.00 to 8.98) |
Collected over From Baseline (Day 1) to end of Safety Follow-Up Visit (up to Day 140). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bimekizumab-SS-2mL (Test 1) | 0/18 (0%) | 0/18 (0%) | 12/18 (66.7%) |
| Bimekizumab-SS-2x1mL (Reference 1) | 0/18 (0%) | 0/18 (0%) | 8/18 (44.4%) |
| Bimekizumab-AI-2mL (Test 2) | 0/17 (0%) | 0/17 (0%) | 12/17 (70.6%) |
| Bimekizumab-AI-2x1mL (Reference 2) | 0/18 (0%) | 0/18 (0%) | 7/18 (38.9%) |
| Event | Bimekizumab-SS-2mL (Test 1) | Bimekizumab-SS-2x1mL (Reference 1) | Bimekizumab-AI-2mL (Test 2) | Bimekizumab-AI-2x1mL (Reference 2) |
|---|---|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 1/18 | 2/18 | 4/17 | 0/18 |
| HeadacheNervous system disorders | 4/18 | 4/18 | 3/17 | 1/18 |
| Injection site haematomaGeneral disorders | 1/18 | 0/18 | 0/17 | 3/18 |
| Dry mouthGastrointestinal disorders | 0/18 | 1/18 | 2/17 | 0/18 |
| NauseaGastrointestinal disorders | 0/18 | 2/18 | 0/17 | 0/18 |
| Oral herpesInfections and infestations | 2/18 | 1/18 | 0/17 | 0/18 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/18 | 0/18 | 1/17 | 2/18 |
| Dry skinSkin and subcutaneous tissue disorders | 2/18 | 0/18 | 0/17 | 0/18 |
| FlatulenceGastrointestinal disorders | 0/18 | 0/18 | 1/17 | 0/18 |
| Gingival discomfortGastrointestinal disorders | 0/18 | 0/18 | 1/17 | 0/18 |
Baseline Characteristics refer to the Full Analysis Set (FAS) which consisted of all randomized study participants who received full or partial investigational medicinal product (IMP) according to the treatment the study participants actually received.
| Age, Categorical(Participants) | Bimekizumab-SS-2mL (Test 1) | Bimekizumab-SS-2x1mL (Reference 1) | Bimekizumab-AI-2mL (Test 2) | Bimekizumab-AI-2x1mL (Reference 2) | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 17 | 17 | 16 | 16 | 66 |
| >=65 years | 1 | 1 | 1 | 2 | 5 |
| Age, Continuous(years) | Bimekizumab-SS-2mL (Test 1) | Bimekizumab-SS-2x1mL (Reference 1) | Bimekizumab-AI-2mL (Test 2) | Bimekizumab-AI-2x1mL (Reference 2) | Total |
|---|---|---|---|---|---|
| Mean | 52.6 ± 12.8 | 51.1 ± 15.8 | 46.8 ± 15.7 | 46.7 ± 15.7 | 49.3 ± 15.0 |
| Sex: Female, Male(Participants) | Bimekizumab-SS-2mL (Test 1) | Bimekizumab-SS-2x1mL (Reference 1) | Bimekizumab-AI-2mL (Test 2) | Bimekizumab-AI-2x1mL (Reference 2) | Total |
|---|---|---|---|---|---|
| Female | 12 | 13 | 13 | 13 | 51 |
| Male | 6 | 5 | 4 | 5 | 20 |
| Race/Ethnicity, Customized(Participants) | Bimekizumab-SS-2mL (Test 1) | Bimekizumab-SS-2x1mL (Reference 1) | Bimekizumab-AI-2mL (Test 2) | Bimekizumab-AI-2x1mL (Reference 2) | Total |
|---|---|---|---|---|---|
| White | 17 | 17 | 17 | 18 | 69 |
| Other/Black | 0 | 1 | 0 | 0 | 1 |
| Other/Caucasian | 1 | 0 | 0 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Bimekizumab-SS-2mL (Test 1) | Bimekizumab-SS-2x1mL (Reference 1) | Bimekizumab-AI-2mL (Test 2) | Bimekizumab-AI-2x1mL (Reference 2) | Total |
|---|---|---|---|---|---|
| Not Hispanic or Latino | 18 | 18 | 17 | 18 | 71 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Data from Phase 1 trials in Healthy Volunteers is outside of UCB's data sharing policy and is unavailable for sharing.
Ran from Feb 2020 to primary completion in Apr 2021, 14 months.
Results were first posted in Apr 2025, 3 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bimekizumab